Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%
Key Highlights
- ➤Q3 revenue $30.80 million, up 42.6% year over year
- ➤Pharma revenue $16.62 million, up 109.8%, with 62 programs added
- ➤Operating margin 23.8%, up from 7.3% in Q3’25
- ➤Full-year 2026 profitability guidance raised while revenue outlook remains $114.0M–$117.0M
- ➤113 plasma centers transitioning providers, threatening $1.5 million Q4 revenue
Expert Statements
Mark Newcomer, President and CEO of Paysign
“This was a strong quarter, with patient affordability continuing to compound.”
Mark Newcomer, President and CEO of Paysign
“We expanded to 167 active programs and increased the quarterly revenue per program by approximately 32% to $99,524.”
Mark Newcomer, President and CEO of Paysign
“As that business becomes a larger share of our total revenue, we’re seeing gross margin and operating margin expand together, which is translating into higher Adjusted EBITDA.”
Mark Newcomer, President and CEO of Paysign
“Separately, our plasma business continued to generate consistent results, supporting investment in our software business.”
Mark Newcomer, President and CEO of Paysign
“Patient affordability is driving our business, and we are seeing demand and momentum continue to build.”
Mark Newcomer, President and CEO of Paysign
“Plasma remains an important part of our business, and our experience as one of the leading processors in the industry has given us the insights to understand the challenges plasma centers face.”
Mark Newcomer, President and CEO of Paysign
“That understanding has shaped a software platform that we believe, if cleared by regulators, will offer our customers a value-added way to streamline and more effectively operate their business.”
Mark Newcomer, President and CEO of Paysign
“The operating and profitability margins for patient affordability are higher than those of our legacy payment processing in plasma, and as we have diversified our business, our corporate margin profile has improved.”
Mark Newcomer, President and CEO of Paysign
“We would expect our software platform to further enhance that dynamic and unlock incremental operating leverage.”
Jeff Baker, Chief Financial Officer of Paysign
“Patient affordability momentum carried through the third quarter, and it shows in the results.”
Jeff Baker, Chief Financial Officer of Paysign
“Revenue, gross margin, net income and Adjusted EBITDA all finished above the high end of our third quarter guidance.”
Jeff Baker, Chief Financial Officer of Paysign
“That strength, combined with the visibility into additional program launches, gives us confidence we’ll land within our revenue outlook of $114.0 million to $117.0 million but exceed our prior full-year profitability outlook, even after accounting for the 113 centers that we anticipate transitioning to another provider during the fourth quarter.”
Jeff Baker, Chief Financial Officer of Paysign
“Patient affordability’s growth is the kind of diversification we set out to build, giving us a second source of growth that we believe can help offset changes like this.”
Jeff Baker, Chief Financial Officer of Paysign
“As we look to 2027, the growth we expect from patient affordability remains on track, and the transition of these centers does not change that trajectory.”
Jeff Baker, Chief Financial Officer of Paysign
“Beyond that, we expect our software platform to represent the next step in that evolution, an incremental opportunity layered on top of our existing business.”
Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%
Patient Affordability Growth Drives Revenue and Margin Expansion
Get started
Create a free account to read the full story.